$0.50
-0.01 (-2.85%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ATYR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 7 with posted results
Held by 12 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +7 more) · FINRA short interest 11.8 days to cover (settled 2026-07-31) · insider 90d: 1 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)NCT05892614Absolute change from baseline in forced vital capacity (FVC) in mLRandomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: efzofitimod 450 mg, efzofitimod 270 mg, Placebo | Interstitial Lung Disease | 25 | Apr 2026 | 2025-05-07 |
| Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary SarcoidosisNCT05415137Change from baseline in mean daily oral corticosteroid (OCS) dose at Week 48Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg, Placebo | Pulmonary Sarcoidosis | 268 | 2025-06-25actual | 2026-06-04 |
| Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary SarcoidosisNCT03824392results2023-07-18Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Biological: Efzofitimod 1.0 mg/kg or Placebo, Efzofitimod 3.0 mg/kg or Placebo, Efzofitimod 5.0 mg/kg or Placebo | Pulmonary Sarcoidosis | 37 | 2021-06-29actual | 2023-07-18 |
| Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19NCT04412668results2023-08-18Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Efzofitimod 1 mg/kg, Efzofitimod 3 mg/kg, Placebo | SARS-CoV-2 (COVID-19) Severe Pneumonia | 36 | 2020-10-23actual | 2023-08-18 |
| Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD)NCT02836418results2023-12-22Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: ATYR1940 | Facioscapulohumeral Muscular Dystrophy, Limb Girdle Muscular Dystrophy | 8 | 2017-04-18actual | 2023-12-22 |
| Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular DystrophyNCT02603562results2023-10-19Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 1/2 | Completed | Biological: ATYR1940 | Facioscapulohumeral Muscular Dystrophy (FSHD) | 8 | 2016-12-12actual | 2023-10-19 |
| Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)NCT02579239results2023-10-19Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Biological: ATYR1940, Placebo | Limb-Girdle Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy | 18 | 2016-10-05actual | 2023-10-19 |
| Safety, Tolerability, Pharmacokinetics (PK), and Activity of ATYR1940 in Participants With Muscular Dystrophy - Study ExtensionNCT02531217results2023-08-18Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 1/2 | Completed | Biological: ATYR1940 | Facioscapulohumeral Muscular Dystrophy | 9 | 2016-05-26actual | 2023-08-18 |
| Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular DystrophyNCT02239224results2021-08-11Number of Participants With Treatment Emergent Adverse Events (TEAEs)Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Biological: Placebo, ATYR1940 | Facioscapulohumeral Muscular Dystrophy (FSHD) | 20 | 2015-12-14actual | 2021-08-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19